Pharmacokinetics of new oral hepatitis C antiviral drugs (Q30422746)

21 June 2017

title

Pharmacokinetics of new oral hepatitis C antiviral drugs (English)

1 reference

21 June 2017

1 reference

Eugenia Vispo

1

1 reference

21 June 2017

Pablo Barreiro

series ordinal

2

1 reference

21 June 2017

Vicente Soriano

series ordinal

3

1 reference

21 June 2017

language of work or name

English

0 references

publication date

25 October 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

21 June 2017

published in

1 reference

21 June 2017

volume

9

1 reference

21 June 2017

issue

1

1 reference

21 June 2017

page(s)

5-16

1 reference

EASL Clinical Practice Guidelines: Management of hepatitis C virus infection

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Preclinical Characterization of BI 201335, a C-Terminal Carboxylic Acid Inhibitor of the Hepatitis C Virus NS3-NS4A Protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Structural Analysis of the Hepatitis C Virus RNA Polymerase in Complex with Ribonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2013.729577

10.1517/17425255.2013.729577

21 January 2018

Identifiers

DOI

1 reference

release_2mphopzmonhztgxgyhiye76p6m

21 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2mphopzmonhztgxgyhiye76p6m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference